Yaoundé, Cameroon (15 November 2005)--Two genetic conditions--sickle cell trait and a mild version of the blood disorder known as thalassemia--that by themselves give millions of Africans natural protection against malaria, can be rendered essentially useless when they occur together, according to a new study of Kenyan children that is to be discussed today at the Fourth Multilateral Initiative on Malaria Pan-African Malaria Conference in Yaoundé, Cameroon.
"We've looked at these traits individually and we expected that if people had both of them, they would be really protected," said Tom Williams, a Wellcome Senior Research Fellow at the Kenya Medical Research Institute (KEMRI) and the study's lead author. "But it turns out that when you start combining the two, you can lose the effect of both."
With malaria researchers eager to find and understand more about genetic traits that confer protection against malaria, the study--recently published in Nature Genetics--shows how challenging it can be to pinpoint protective genes and, moreover, predict how they might be influenced by other traits. (Thursday, 11:50 a.m., Iroko Hall, Parallel Session 23, Presentation 148)
"This is an important finding in part because a huge effort is being poured into malaria genomics and the search for genetic associations with malaria," Williams said. "Our study shows that it can be very complicated to turn up genetic associations and properly understand them. If one trait can interfere with the effects of another, you may miss an association where one truly exists. Conversely, you may find a trait that seems to provide protection but not see how other traits could alter the effect."
Nonetheless, Williams said the finding--which involved chronicling the genetic and malarial status of more than 2,000 children, most starting at birth--can help scientists learn more about discrete, if complex, biological mechanisms at work in naturally acquired immunity.
For several years Williams' research has probed how certain genetic factors provide Africans with a degree of natural protection against malaria. A key focus of his work has been the underlying effects of the sickle cell trait, which became relatively common in humans as an evolutionary, protective genetic response to thousands of years of exposure to malaria.
Individuals with sickle cell trait inherit one normal hemoglobin gene from one parent and a sickle hemoglobin gene from another. (They don't have sickle disease, which occurs when someone inherits two copies of the sickle gene, one from each parent.) Studies have shown that when children with the sickle trait are exposed to malaria, they suffer far fewer parasites and are 90 percent less likely to be hospitalized by a malaria infection than those without the trait. The protective effect increases with age.
Meanwhile, Williams said researchers have long known that a genetic variation known as alpha thalassemia--which is common in sub-Saharan Africa but, unlike beta thalassemia, is not associated with major health problems--also helps people fight malaria. While not offering as much protection as the sickle trait, Williams said children with the thalassemia trait are less likely to die from a malaria infection because it prevents severe anemia, which can complicate other malaria-induced conditions.
The degree to which the interaction between the traits dilutes their protective effect depends on the type of alpha thalassemia gene involved. (There are two sub-varieties.) But Williams said when the sickle trait exists alongside the type found routinely in malaria endemic regions of Africa, "all the good work of these genes is lost and you end up with the same degree of risk as someone who has neither trait."
Williams said the finding does not affect treatment decisions but is valuable to researchers as a stark example of the genetic interactions that can occur in malaria. He said the research also demonstrates why certain critical issues related to malaria cannot be resolved unless there are scientists equipped with modern technology working directly with people in the areas of Africa most affected by malaria. For example, Williams said, his insights would not have been possible if he had not been working directly with Africans who are routinely exposed to malaria and employing a relatively new technology that allows scientists to quickly screen the genetic profile of a large number of people.
"This is another example of the incredible new insights that emerge from supporting malaria research in Africa," said Andreas Heddini, the MIM Secretariat coordinator. "There are many scientists interested in malaria genetics. But as this study shows, findings that come only from the laboratory will be limited unless they are supported by strong evidence from population studies in Africa."
Interest in fighting malaria by studying particular genetic factors related to the disease has increased over the past few years following the sequencing of the genomes of the most deadly form of malaria and its mosquito carrier.
Daniel J. Carucci, director of the Grand Challenges in Global Health initiative at the Foundation for the National Institutes of Health and a co-author of the genome sequence for the malaria parasite, will give a keynote address at MIM that will discuss how genomic data is advancing malaria research and what's needed to realize its full potential. (Tuesday, 9:00 a.m., Bubinga Hall, Plenary Session I, Keynote Lecture)
For example, thanks to the genome sequence, researchers now have in their hands powerful "gene chips" that contain the entire malaria genome and can be used to quickly screen parasites for evidence of virulence or drug resistance, or to uncover how they have evolved to avoid human immune responses. And with the sequence publicly available, leading genomics experts who had done little with malaria are now focusing their talent and technology on the disease.
"But resources and personnel are limited," said Carucci. "To maintain momentum, a large-scale effort must be undertaken to distill from the genome data critical information that will give researchers what they need to select those new targets for drugs and vaccines that are most likely to yield success."
To provide coordinated international approach to fighting malaria, the Roll Back Malaria Partnership (RBM) (www.rollbackmalaria.org) was launched in 1998 by the World Health Organization, the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP) and the World Bank. The Partnership now brings together governments of countries affected by malaria, their bilateral and multilateral development partners, the private sector, non-governmental and community-based organizations, foundations, and research and academic institutions around the common goal of halving the global burden of malaria by 2010. World Malaria Report 2005 http://rbm.who.int/wmr2005/
The Multilateral Initiative on Malaria (MIM) (www.mim.su.se), launched in Dakar, Senegal in 1997, is an international alliance of organizations and individuals seeking to maximize the impact of scientific research against malaria in Africa to ensure that research findings yield practical health benefits. The MIM Secretariat was previously hosted for 3-years terms by the Wellcome Trust (UK) and the Fogarty International Center at the National Institutes of Health (US). In 2003, the Secretariat moved to Stockholm, Sweden, where it is hosted by the Karolinska Institute and Stockholm University.
For further information, please contact:
Cameroon
MIM, Wilfred Mbacham, T +237 757 91 80, wfmbacham@yahoo.com
Africa
Massive Effort London UK, Louis Da Gama, T +44 208 357 7413, M +44 7990 810642, ldagama@gmail.com
Massive Effort South Africa, Vanessa Peter, T +27 82 327 6286, v_bester@yahoo.co.uk
Europe, Scandinavia and Asia
Good Company, Maria Dalayman T +46-8-545 805 54, M +46 70 685 40 05, maria@goodcompany.se
France and Belgium
Massive Effort Paris, Patrick Bertrand, T+33 6 60 04 04 42, P.bertrand@noos.fr
UK Peter Robbs Consultants Ltd, Cathy Bartley, T +44 (0) 207 635 1593, M +44 (0)79 58 56 16 71, cathy.bartley@ukonline.co.uk
US/Canada
Burness Communications, Ellen Wilson, T +1 301 652 1558, ext 108, M +1 301 922 4969,
ewilson@burnesscommunications.com
or visit our pressroom at http://www.rollbackmalaria.org/forumV/pressinfo.htm.
You can also find information about malaria on the following links: The PATH Malaria Vaccine Initiative: www.malariavaccine.org, Medicines for Malaria Venture: www.mmv.org and Special Programme for Research and Training in Tropical Diseases (TDR) World Health Organization: www.who.int/tdr
The conference organizers and the Kaiser Family Foundation, through its online news summary and webcasting service, kaisernetwork.org, are working together to bring online coverage of the conference to those unable to attend. Kaisernetwork.org's comprehensive online coverage will include webcasts and transcripts of each day's plenary sessions and selected other sessions, text summaries of select sessions, and interviews with newsmakers. Slide presentations from select sessions will also be available. Access the coverage at http://www.kaisernetwork.org/malaria2005.